Orthogonal transcriptional modulation and gene editing using multiple CRISPR-Cas systems

Authors:
Broksø AD, Bendixen L, Fammé S, Mikkelsen K, Jensen TI, Bak RO
In:
Source: Mol Ther
Publication Date: (2025)
Issue: 33(1): 71-89
Research Area:
Cancer Research/Cell Biology
Immunotherapy / Hematology
Gene Expression
Basic Research
Molecular Biology
Regenerative medicine
Cells used in publication:
Jurkat
Species: human
Tissue Origin: blood
T cell, human stim.
Species: human
Tissue Origin: blood
Culture Media:
Platform:
4D-Nucleofector® X-Unit
Experiment

Cell culture
Jurkat cells were cultured in RPMI-1640 medium supplemented with 5% heat-inactivated fetal calf serum (FCS), 2mM L-glutamine, 100 U/ mL penicillin, and 100 mg/mL streptomycin. Peripheral blood mononuclear cells were isolated from de-identified buffy coats obtained from healthy adult donors from the Aarhus University Hospital Blood Bank by Ficoll-Plaque plus density gradient and from these, primary human T cells were purified by negative selection with the EasySep human T cell isolation kit (STEMCELL Technologies). The primary human T cells were cultured in X-VIVO 15 medium (Lonza) supplemented with 5% human albumin serum (Merck) and 10 ng/mL IL-7 and IL-2 (Peprotech). The cells were activated for 3 days with Dynabeads human T-activator CD3/CD28 (Thermo Fisher Scientific) at a 1:1 cell-to-bead ratio.

Electroporation
All cells were electroporated using the 4D-nucleofector device from Lonza (X unit) in 20-µL-format Nucleocuvette strips. Cells were electroporated in the following electroporation buffers and programs. Jurkat cells: Opti-MEM (Thermo Fisher Scientific), CM138-P3; primary human T cells: solution 1M, EO115-P3.49 For CRISPRa and CRISPRi singleplex RNA-based delivery experiments, unless otherwise specified, cells were electroporated with 0.095 µg/mL mRNA + 0.05 mg/ µL of each of the sgRNAs. For orthogonal CRISPRa and CRISPRi experiments, cells were electroporated with 0.095 µg/µL dSpCas9-VPR mRNA along with 0.0125 µg/µL of each sgRNA for CD123 (#1–4) and NGFR (#1–4), and 0.095 µg/µL dSaCas9-KOX1 mRNA along with 0.0167 µg/µL of each sgRNA for CD5 (#1–3) and CD3E (#1–3). In primary human T cells for CRISPRa and CRISPRi experiments for trimodal engineering, at the optimized condition cells were electroporated with 0.095 mg/mL dSpCas9-VPR mRNA + 0.0125 µg/µL of each sgRNA for CD123 (#1–4) and 0.095 µg/µL dSaCas9-KOX1 + 0.05 µg/ µL of each sgRNA for CD5 (#1–3).

For gene editing of TRAC with nuclease-active Cas9 protein (Alt-R S.p. Cas9 Nuclease V3; IDT), Cas9 and sgRNAs were incubated for 15 min at room temperature and later stored at 4°C prior to electroporation. RNP complexes were mixed with cells resuspended in 1 M electroporation buffer.50 Cas9 protein and sgRNAs were at a final concentration of 0.320 µg/µL and 0.160 µg/µL, respectively.

Abstract

CRISPR-Cas-based transcriptional activation (CRISPRa) and interference (CRISPRi) enable transient programmable gene regulation by recruitment or fusion of transcriptional regulators to nuclease-deficient Cas (dCas). Here, we expand on the emerging area of transcriptional engineering and RNA delivery by benchmarking combinations of RNA-delivered dCas and transcriptional modulators. We utilize dCas9 from Staphylococcus aureus and Streptococcus pyogenes for orthogonal transcriptional modulation to upregulate one set of genes while downregulating another. We also establish trimodal genetic engineering by combining orthogonal transcriptional regulation with gene knockout by Cas12a (Acidaminococcus; AsCas12a) ribonucleoprotein delivery. To simplify trimodal engineering, we explore optimal parameters for implementing truncated single guide RNAs (sgRNAs) to make use of SpCas9 for knockout and CRISPRa. We find the Cas9 protein/sgRNA ratio to be crucial for avoiding sgRNA cross-complexation and for balancing knockout and activation efficiencies. We demonstrate high efficiencies of trimodal genetic engineering in primary human T cells while preserving basic T cell health and functionality. This study highlights the versatility and potential of complex genetic engineering using multiple CRISPR-Cas systems in a simple one-step process yielding transient transcriptome modulation and permanent DNA changes. We believe such elaborate engineering can be implemented in regenerative medicine and therapies to facilitate more sophisticated treatments.